Efficacy and Safety of Different Doses of Rosuvastatin in Treatment of Elderly Coronary Heart Disease Patients

Objective: To explore the efficacy and safety of different doses of rosuvastatin in treatment of elderly coronary heart disease patients. Methods: Two hundred and ten hospitalized patients(including 75 years old and higher) diagnosed as Coronary atherosclerotic cardiopathy( CHD) were evenly divided into group A and group B by random from June 2012 to June 2013. The patients in group A were treated with oral rosuvastatin at the dose of 10 mg/d, and the patients in group B were treated with oral rosuvastatin at the dose of 20 mg/d. The other cooperative medication methods were collected. Biochemical indicators were measured before and after one, six, twelve months of treatment, including Low-density Lipoprotein Cholesterol(LDL-C), Total Cholesterol(TC), High Sensitivity C Reactive Protein(hs-CRP), Triglyceride(TG), High-density Lipoprotein Cholesterol(HDL-C), Alanine-Aminotransferase(ALT), and Intima-media thickness(IMT). Result: There were significant decrease in LDL-C, TC, hs-CRP, and TG between the two groups before and after one, six, and twelve months of treatment(P0.05). After treatment, the levels of LDL-C, TC, TG, and hs-CRP of group B were significantly lower than that of group A(P 0.05), and HDL-C higher level was significantly higher than in group A. There was no significant difference between the two groups in the level of ALT and the incidences of adverse reactions(P0.05). Both group A and group B had no adverse cardiac events(MACE) and termination of the experiments. Conclusion: For elderly patients with coronary heart disease in our country, rosuvastatin medication is beneficial, and higher dose of rosuvastatin is safe and more effective against CHD.